Indo Borax buys 64.26% of Kronox in ₹246 crore deal

Deal closure shifts control to Indo Borax

Indo Borax & Chemicals Limited has completed the acquisition of a controlling stake in Kronox Lab Sciences Limited, formally becoming the majority shareholder. Kronox disclosed that the transfer of a 64.26% equity stake to Indo Borax was completed on September 29, 2026. The transaction covers 2,38,44,000 equity shares, which the company said represent 64.26% of Kronox’s total paid-up equity share capital. The deal marks a change of control at the Vadodara-headquartered specialty chemicals company. The completion disclosure was signed by Sunil Malhotra, Director at Indo Borax & Chemicals, who requested stock exchanges to take the information on record. Indo Borax is listed on BSE (524342), while Kronox Lab Sciences is listed on NSE (KRONOX), as referenced in the deal disclosures. Alongside Indo Borax, Zenrock Chemicals Private Limited is named as a person acting in concert (PAC) in relation to the broader acquisition and open offer process.

What was acquired and at what price

Indo Borax agreed to buy the promoter stake for an aggregate consideration of ₹246.12 crore. The share purchase agreement (SPA) referenced in the disclosures is dated August 20, 2026, and the closing was confirmed on September 29, 2026. Another disclosure described the purchase price as INR 2.5 billion for the same 64.26% stake, aligning broadly with the ₹246.12 crore consideration. The shares were acquired from Kronox’s outgoing promoters: Ketan Vinodchandra Ramani, Pritesh Vinodchandra Ramani, and Jogindersingh Gianchand Jaswal. Company filings also stated that Indo Borax would appoint three nominee directors to the board of Kronox as part of the post-acquisition governance reset. With the stake transfer completed, Indo Borax is now the controlling shareholder in Kronox Lab Sciences.

Timeline: board approval, SPA, and closing

The acquisition was approved by Indo Borax’s Board of Directors at a meeting held on August 20, 2026. That board approval cleared the execution of the SPA for acquiring 64.26% of Kronox. The transaction then closed on September 29, 2026, when 2,38,44,000 equity shares were transferred to Indo Borax. The closing date is also the effective date referenced for the incoming executive appointments at Kronox, subject to shareholder approval. Disclosures indicate that Zenrock Chemicals Private Limited was also party to the deal documents, reflecting its role as PAC in the wider acquisition and open offer process. These steps together establish the formal transfer of control from the outgoing promoter group to Indo Borax.

Key transaction details at a glance

Mandatory open offer also referenced

Disclosures connected with the acquisition stated that Indo Borax is also launching a mandatory joint open offer for an additional 25.79% stake. While the completion announcement focuses on the promoter stake transfer, the open offer reference signals that the transaction is structured as a change-of-control deal with a follow-on public shareholder process. Zenrock Chemicals Private Limited is mentioned as a person acting in concert for the broader acquisition and open offer framework. No additional open offer price or timeline details were included in the provided information. As a result, the confirmed facts remain the controlling stake purchase, the closing date, and the percentage targeted in the open offer.

New board and leadership team approved

Following the change of control, Kronox approved a new leadership structure and board appointments. The company stated that the new board is led by Suresh Kalra as Managing Director and CEO, replacing the outgoing management team. The board also approved five-year executive appointments effective September 29, 2026, subject to shareholder approval. In addition, the company approved the appointment of Shashikant Bharuka as Chief Financial Officer and Key Managerial Personnel.

Appointments: roles, tenure, and executive backgrounds

Suresh Kalra was appointed Managing Director and CEO for a five-year term, and the company noted he brings over 25 years of leadership experience across the global chemicals sector. The disclosure referenced his prior roles, including CEO and Whole-time Director at Aquapharm Chemical Limited, Managing Director (India) and President (Asia) at Hubergroup Germany, and MD and VP at SI Group (USA). Sunil Malhotra was appointed Whole-time Director for a five-year term, with the company describing him as a seasoned entrepreneur with 38 years of experience and noting his role as Designated Partner at She Capital LLP. Harsh Malhotra was appointed Executive Director for a five-year term, and the company cited his decade of operational leadership at Amazon across global supply chains, along with academic credentials including a Master of Science in International Business from Ivey Business School and a Bachelor of Commerce from McGill University. Shashikant Bharuka was appointed CFO and KMP, and the company stated he is a qualified CA and CS with over 24 years of post-qualification experience, including stints across pharmaceutical companies such as Lupin, Unichem, Ajanta Pharma, and IPCA Laboratories.

Additional directors and board reconstitution

Beyond the executive appointments, the board also approved the appointment of Amit Kumar Sharma, Anuradha Suneet Maheshwari, and Dhananjay Tapasvi as additional directors, based on the recommendation of the company’s Nomination and Remuneration Committee. Separately, deal disclosures stated that Indo Borax would appoint three nominee directors to Kronox’s board, and that the outgoing promoters would resign from the board. The disclosures do not list the names of the nominee directors in the provided information. The combination of promoter resignations, nominee director rights, and new executive leadership signals a full governance reset aligned with Indo Borax’s majority ownership.

Market impact: what changes for shareholders and oversight

The primary market-relevant development is the formal change in control at a listed specialty chemicals company following the transfer of 64.26% equity ownership. For investors, the closing date of September 29, 2026 is significant because it confirms that the SPA signed on August 20, 2026 has moved from agreement to completion. The disclosed consideration of ₹246.12 crore establishes the negotiated value for the promoter block, which is often used by market participants to compare against prevailing traded prices, even though no stock price data was provided here. The referenced mandatory joint open offer for an additional 25.79% stake is also a key procedural event for public shareholders, since it typically provides an exit opportunity under takeover regulations, though offer terms were not included in the provided text. Operationally and from a governance standpoint, the replacement of the management team and the appointment of a new MD and CEO, along with a new CFO, indicates changes in day-to-day control and reporting structures.

Analysis: why this transaction matters for the chemicals space

This transaction is notable because it combines a majority stake purchase with an immediate board and leadership overhaul, indicating that the acquirer intends to actively direct strategy and operations. The target, Kronox Lab Sciences, is described as a specialty chemicals company headquartered in Vadodara, and Indo Borax’s move positions it as the controlling shareholder. The use of a PAC, Zenrock Chemicals Private Limited, and the mention of a mandatory joint open offer reflect a structured acquisition approach that extends beyond a private promoter-to-acquirer transfer. The board reconstitution and executive appointments, including a five-year MD and CEO term and a designated CFO and KMP appointment, also point to a longer-term operating plan under new ownership, subject to shareholder approvals where required. Just as importantly, the disclosures identify the sellers and clarify that control has shifted, reducing uncertainty around the completion status of the deal.

Conclusion: confirmed completion, board reset, and next steps

Indo Borax & Chemicals has completed the purchase of 2,38,44,000 Kronox Lab Sciences shares, taking its stake to 64.26% and establishing majority control as of September 29, 2026. The acquisition follows the SPA signed on August 20, 2026 and carries a disclosed promoter-stake consideration of ₹246.12 crore. Kronox has approved a new leadership team led by Suresh Kalra as MD and CEO, alongside other board and executive appointments, with key roles set for five-year terms subject to shareholder approval. The deal disclosures also reference a mandatory joint open offer for an additional 25.79% stake, which remains the next confirmed process step mentioned in the provided information.